Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 181
  • Home
  • Print this page
  • Email this page
CASE REPORT
Year : 2021  |  Volume : 8  |  Issue : 1  |  Page : 103-105

Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study


Department of Investigational Cancer Therapeutics (A Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA

Correspondence Address:
PhD, ANP-BC, AOCNP Fedricker D Barber
Department of Investigational Cancer Therapeutics (A Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/apjon.apjon_49_20

Rights and Permissions

Posterior reversible encephalopathy syndrome (PRES) is a rare potential immune-related adverse event (irAE) of checkpoint inhibitors. PRES is a disorder that has a variety of clinical and radiological features, which makes it a challenge for advanced practice registered nurses to diagnose. IrAEs such as PRES require prompt recognition and intervention to optimize clinical outcomes. Author Queries??? AQ1: Please ensure that the patient consent form has been obtained.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed170    
    Printed2    
    Emailed0    
    PDF Downloaded10    
    Comments [Add]    

Recommend this journal